Glenmark Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Key Takeaways

• FY27 set up as a breakout year: Revenue guided to ₹17,000–₹18,000 crore with EBITDA margins of 21–22%, driven by U.S. respiratory launches, India oncology ramp, and RYALTRIS global expansion.
• India business is the star performer: Grew 12.3% in Q4 and 13.5% for the full year, outpacing the IPM and ranking Glenmark as the second fastest-growing top-15 company; all segments outperformed except diabetes, which gets a fix in Q1.
• RYALTRIS crossed \$100 million and is accelerating: Secondary sales grew ~50% in FY26, the brand is now in 55 markets, and Glenmark took over U.S. commercialization directly in April; management expects 30–40%+ growth for the next few years.
• U.S. Q4 missed on timing, not demand: Lower sales from supply chain disruptions and approval timing for Fluticasone products pushed revenue into FY27, where 2–3 respiratory launches and two sole FTF exclusivities are now lined up.
• What to watch next quarter: Whether the GLIPIQ (semaglutide) launch returns the diabetes franchise to growth, the pace of RYALTRIS U.S. self-commercialization ramp, and granular growth driver detail at the upcoming Investor Day.

India Formulations: Outperformance with a Diabetes Fix

• Broad-based market-beating growth: India formulations grew 12.3% in Q4 and 13.5% for FY26, versus IPM growth of 10.1% and 9% respectively, making Glenmark the second fastest-growing company among the top 15 in FY26.
• Dermatology and respiratory gaining share: Dermatology held the #2 rank, respiratory gained share on the back of the NEBZMART GFB nebulizer launch (world's first triple fixed-dose COPD therapy) and other products, while the cardiovascular Telma franchise and oncology portfolio with TEVIMBRA and BRUKINSA all performed well.
• Diabetes the lone laggard, with a clear catalyst: The franchise struggled because remogliflozin lost ground after dapagliflozin went generic, and teneligliptin faced the same dynamic after sitagliptin went generic; the launch of GLIPIQ (semaglutide vials and prefilled pens, approved via a multicenter India trial) is expected to return the segment to growth from Q1 FY27, supported by the Sankalp patient support program to drive therapy initiation.
• Oncology building a multi-year contributor: In-licensed Trastuzumab Rezetecan and Aumolertinib, alongside launched brands TEVIMBRA and BRUKINSA, are expected to meaningfully contribute to India business over the next 2–3 years.

Glenn Saldanha: "Diabetes, as you know, right, there are 2, 3 molecules, right, which we had, which are continuing to struggle, right? So one of them is obviously remogliflozin, right, being an SGLT after dapa went generic, right? We really struggled to gain market share on remo, and the second one was teneligliptin with sitagliptin going generic, right?"

RYALTRIS: The Global Growth Engine

• \$100 million brand with 50% secondary sales growth: RYALTRIS crossed \$100 million in sales in FY26, with secondary sales growing approximately 50% across commercial markets; the brand is now the leading nasal spray in allergic rhinitis in most emerging markets and is present in 55 countries.
• U.S. self-commercialization now live: As of April 2026, Glenmark ended its partnership with Hikma and began commercializing RYALTRIS directly in the U.S., with management believing the internal team can execute better.
• China and Thailand launched in Q4: Regional partners Grand Pharma and Organon launched the product in China and Thailand during the quarter; China launch, once reimbursement is secured, is expected to become a significant contributor.
• Pipeline of new market entries: Brazil approval received with commercial launch planned this year; an additional 8–10 markets expected to launch over the next few quarters.
• Growth trajectory: Management expects 30–40%+ annual growth on the brand for at least the next few years.

Glenn Saldanha: "RYALTRIS is a huge product. We have over $100 million of sales last year. The brand at secondary sales growth is about 50% on the brand right now. So it's doing exceedingly well."

U.S. Business: Q4 Timing Miss, FY27 Pipeline Loaded

• Q4 shortfall was a spillover, not a loss: U.S. sales in Q4 were lower than targeted because of supply chain disruptions and go-to-market issues for Fluticasone Nasal Spray and Flovent; the revenue spilled into FY27 rather than being lost.
• Respiratory approvals stack up: Fluticasone MDI 44 mcg (generic to FloVent) was approved with Competitive Generic Therapy designation and 180-day exclusivity; Fluticasone Nasal Spray OTC was also approved; 2–3 additional respiratory products are targeted for launch in FY27.
• Two sole FTF exclusivities coming: Two sole first-to-file products are expected at the end of Q3 and Q4 FY27, adding a high-margin layer to U.S. growth.
• Monroe facility back online: The facility received Voluntary Action Indicated classification from the U.S. FDA after the November 2025 inspection, enabling restart of commercial manufacturing.
• Injectable portfolio expanding: The U.S. injectable franchise now includes approximately 20 products commercialized through partners.

Glenn Saldanha: "So I think if everything comes through, it will be a strong year for the respiratory franchise. Additionally, we have as I said, the 2 sole FTFs."

Europe and Emerging Markets: Steady, Broad-Based Growth

• Europe driven by branded business: Strong growth came from the branded portfolio across key markets, with Central and Eastern Europe delivering double-digit growth across all key markets, and Western Europe showing good growth in Germany and the Netherlands.
• WINLEVI European launch underway: European approval received; launched in the U.K. in Q1 FY26; marketing authorization approved for licensed European markets with launches planned in FY27.
• Respiratory expansion planned: Glenmark intends to launch 2–3 additional respiratory products in Europe during FY27.
• Emerging markets performing well: Good growth in LATAM and MEA regions, aided by multiple respiratory product launches in FY26; APAC delivered double-digit secondary sales growth in Malaysia and Australia.

IGI and the Innovative Pipeline: Early-Stage, High-Upside

• Landmark AbbVie deal validates the platform: IGI secured a licensing deal with AbbVie for ISB 2001, with USD 70 crore upfront, total potential of USD 192.5 crore plus tiered double-digit royalties; Glenmark retains commercialization rights across Emerging Markets post-approval.
• Pipeline advancing toward the clinic: ISB-2301 clinical candidate selected, with IND submission intended for end of calendar year 2026; ISB-880 (LAD191), licensed to Almirall, is in Phase II for Hidradenitis Suppurativa with plans for a proof-of-concept study in an additional inflammatory skin disease.
• Oncology assets progressing globally: A global multicenter Phase III trial for Trastuzumab Rezetecan in neo-adjuvant/adjuvant non-small cell lung cancer has been initiated; Aumolertinib marketing authorization submissions were filed in multiple markets as of March 2026, with first commercial launch anticipated in H2 FY27; QINHAYO (envafolimab) first commercial launch expected in FY28.
• IGI leadership transition: Cyril Konto was replaced by former CMO Lida Pacaud approximately 6–8 months ago.

Financial Position: Clean Balance Sheet, Margin Reset

• Gross debt free target achieved: Glenmark ended FY26 gross debt free while maintaining a healthy cash position, meeting its stated guidance.
• Core operating margin pressured by temporary factors: Lower absorption of fixed costs in the U.S. (due to the Q4 timing miss) and higher distribution expenses linked to the geopolitical and supply chain environment weighed on margins in the quarter.
• Receivables increase explained: Three drivers: the planned stop of pre-collections (flagged at H1), delayed MEA region collections due to war conditions, and currency translation impact on debtors.
• Exceptional items largely resolved: The primary component was a U.S. litigation settlement and associated legal costs, with no liabilities assumed in these settlements; 1–2 outstanding cases remain and will take a few more years to settle.
• Working capital discipline maintained: Management committed to staying best-in-class at 115–120 days and continuing to release cash from efficiencies.

Anurag Mantri: "we are clearly maintaining that we will be the best in the industry and 115 to 120 days, we will be below that."

Guidance & Commitments

Key Metrics